Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $38.29 million. The enterprise value is $14.52 million.

Market Cap	38.29M
Enterprise Value	14.52M

Important Dates

The last earnings date was Thursday, March 27, 2025, after market close.

Earnings Date	Mar 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 10.78 million shares outstanding. The number of shares has decreased by -0.74% in one year.

Current Share Class	10.78M
Shares Outstanding	10.78M
Shares Change (YoY)	-0.74%
Shares Change (QoQ)	+0.19%
Owned by Insiders (%)	0.39%
Owned by Institutions (%)	12.17%
Float	7.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.81
P/TBV Ratio	1.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.01.

Current Ratio	5.83
Quick Ratio	5.54
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -66.93% and return on invested capital (ROIC) is -44.38%.

Return on Equity (ROE)	-66.93%
Return on Assets (ROA)	-40.12%
Return on Invested Capital (ROIC)	-44.38%
Return on Capital Employed (ROCE)	-104.59%
Revenue Per Employee	n/a
Profits Per Employee	-$989,582
Employee Count	21
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -63.70% in the last 52 weeks. The beta is 1.63, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.63
52-Week Price Change	-63.70%
50-Day Moving Average	4.23
200-Day Moving Average	3.95
Relative Strength Index (RSI)	39.80
Average Volume (20 Days)	29,639

Short Selling Information

The latest short interest is 239,399, so 2.22% of the outstanding shares have been sold short.

Short Interest	239,399
Short Previous Month	232,366
Short % of Shares Out	2.22%
Short % of Float	3.01%
Short Ratio (days to cover)	5.27

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-22.22M
Pretax Income	-17.75M
Net Income	-20.78M
EBITDA	-22.20M
EBIT	-22.22M
Earnings Per Share (EPS)	-$1.93

Full Income Statement

Balance Sheet

The company has $24.01 million in cash and $243,657 in debt, giving a net cash position of $23.77 million or $2.20 per share.

Cash & Cash Equivalents	24.01M
Total Debt	243,657
Net Cash	23.77M
Net Cash Per Share	$2.20
Equity (Book Value)	21.19M
Book Value Per Share	1.96
Working Capital	20.92M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$17.81 million and capital expenditures -$12,595, giving a free cash flow of -$17.83 million.

Operating Cash Flow	-17.81M
Capital Expenditures	-12,595
Free Cash Flow	-17.83M
FCF Per Share	-$1.65

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.74%
Shareholder Yield	n/a
Earnings Yield	-54.28%
FCF Yield	-46.56%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1